Business Description
Achieve Life Sciences Inc
NAICS : 325413
SIC : 2835
ISIN : US0044685008
Total Employee Number:
28Description
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.96 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 1.4 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31.4 | |||||
3-Year EPS without NRI Growth Rate | 32.3 | |||||
3-Year FCF Growth Rate | 31.6 | |||||
3-Year Book Growth Rate | -4.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.85 | |||||
9-Day RSI | 53.27 | |||||
14-Day RSI | 56.23 | |||||
3-1 Month Momentum % | 64.76 | |||||
6-1 Month Momentum % | 3.42 | |||||
12-1 Month Momentum % | 146.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.62 | |||||
Quick Ratio | 2.62 | |||||
Cash Ratio | 2.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -43.8 | |||||
Shareholder Yield % | -0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -220.75 | |||||
ROA % | -121.91 | |||||
ROIC % | -710.86 | |||||
3-Year ROIIC % | 124.56 | |||||
ROC (Joel Greenblatt) % | -65320.97 | |||||
ROCE % | -153.05 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 30.4 | |||||
Price-to-Tangible-Book | 36.37 | |||||
EV-to-EBIT | -12 | |||||
EV-to-EBITDA | -12.05 | |||||
EV-to-Forward-Revenue | 14.3 | |||||
EV-to-FCF | -13.53 | |||||
| Price-to-Net-Current-Asset-Value | 38.2 | |||||
| Price-to-Net-Cash | 47.01 | |||||
Earnings Yield (Greenblatt) % | -8.33 | |||||
FCF Yield % | -7.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACHV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Achieve Life Sciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.12 | ||
| Beta | 2.8028 | ||
| 3-Year Sharpe Ratio | 0.4 | ||
| 3-Year Sortino Ratio | 0.71 | ||
| Volatility % | 91.31 | ||
| 14-Day RSI | 56.23 | ||
| 14-Day ATR ($) | 0.450514 | ||
| 20-Day SMA ($) | 5.839 | ||
| 12-1 Month Momentum % | 146.78 | ||
| 52-Week Range ($) | 2.25 - 7.11 | ||
| Shares Outstanding (Mil) | 102.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Achieve Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Achieve Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:30 | In 28 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| General meeting for 2026 | 2026-07-02 09:00 | 6.40 (-1.39%) | ||
| Annual report for 2025 | 2026-06-08 | 5.13 (-1.91%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:30 | 5.59 (+8.33%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 5.59 (+8.33%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 08:30 | 4.05 (-1.22%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 4.05 (-1.22%) |
Show
Entries
Achieve Life Sciences Inc Frequently Asked Questions
What is Achieve Life Sciences Inc(ACHV)'s stock price today?
The current price of ACHV is $6.11. The 52 week high of ACHV is $7.11 and 52 week low is $2.25.
When is next earnings date of Achieve Life Sciences Inc(ACHV)?
The next earnings date of Achieve Life Sciences Inc(ACHV) is 2026-08-07 Est..
Does Achieve Life Sciences Inc(ACHV) pay dividends? If so, how much?
Achieve Life Sciences Inc(ACHV) does not pay dividend.
Guru Commentaries on NAS:ACHV
No articles.
Press Release
Articles on Achieve Life Sciences Inc
Headlines
See More- 1
Jun 22, 2026
Achieve Life Sciences jumps despite cytisinicline CRL
Seeking Alpha • 10:24am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers